Literature DB >> 11524321

Resensitization of blood pressure response to mu-opioid peptide agonists after acute desensitization.

H H Szeto1, Y Soong, D Wu, J Fasolo.   

Abstract

IV administration of mu-opioid peptide agonists (DAMGO, DALDA, and [Dmt(1)]DALDA) results in a transient, naloxone-sensitive, increase in blood pressure in awake sheep. Despite significant differences in pharmacokinetics, these blood pressure responses all last < 15 min. The lack of correlation between half-life and duration of action suggested rapid desensitization. When a second dose of the same agonist was repeated 30 min later, the response was completely abolished. An increase in blood pressure and rapid desensitization was also observed with the kappa-opioid agonist (U50488H), whereas delta-agonists (DPDPE and DELT) had no effect on blood pressure. The response to DAMGO was abolished after prior exposure to DAMGO or DALDA, but there was no evidence of cross-desensitization between mu and delta, or mu and kappa, opioid agonists. Full resensitization of the blood pressure response occurred by 4 h for DAMGO (t(1/2) = 15 min) and by 48 h for [Dmt(1)]DALDA (t(1/2) = 1.8 h). These data support our hypothesis that the transient nature of the blood pressure response to mu-opioid agonists is caused by rapid desensitization and suggest that the rate of resensitization is dependent on the pharmacokinetics of the agonist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524321     DOI: 10.1097/00000539-200109000-00010

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  2 in total

1.  Protective role of μ opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice.

Authors:  Francesca Saccani; Laura Anselmi; Ingrid Jaramillo; Simona Bertoni; Elisabetta Barocelli; Catia Sternini
Journal:  J Neurosci Res       Date:  2012-07-17       Impact factor: 4.164

2.  Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.

Authors:  Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-03-21       Impact factor: 4.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.